Best practice in the administration of analgesia in postoncological surgery

Juan P. Cata, Javier Lasala, Dario Bugada

Research output: Contribution to journalArticle

Abstract

The rationale for using multimodal analgesia after any major surgery is achievement of adequate analgesia while avoiding the unwanted effects of large doses of any analgesic, in particular opioids. There are two reasons why we can hypothesize that multimodal analgesia might have a significant impact on cancer-related outcomes in the context of oncological orthopedic surgery. First, because multimodal analgesia is a key component of enhanced-recovery pathways and can accelerate return to intended oncological therapy. And second, because some of the analgesic used in multimodal analgesia (i.e., COX inhibitors, local analgesics and dexamethasone) can induce apoptosis in cancer cells and/or diminish the inflammatory response during surgery which itself can facilitate tumor growth.

Original languageEnglish
Pages (from-to)273-284
Number of pages12
JournalPain Management
Volume5
Issue number4
DOIs
Publication statusPublished - 2015

Fingerprint

Practice Guidelines
Analgesia
Analgesics
Neoplasms
Dexamethasone
Opioid Analgesics
Orthopedics
Apoptosis
Growth
Therapeutics

Keywords

  • cancer
  • enhanced recovery
  • multimodal analgesia
  • surgery
  • survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Best practice in the administration of analgesia in postoncological surgery. / Cata, Juan P.; Lasala, Javier; Bugada, Dario.

In: Pain Management, Vol. 5, No. 4, 2015, p. 273-284.

Research output: Contribution to journalArticle

Cata, Juan P. ; Lasala, Javier ; Bugada, Dario. / Best practice in the administration of analgesia in postoncological surgery. In: Pain Management. 2015 ; Vol. 5, No. 4. pp. 273-284.
@article{38ff97a787a64f51b6fd9f762902f8b3,
title = "Best practice in the administration of analgesia in postoncological surgery",
abstract = "The rationale for using multimodal analgesia after any major surgery is achievement of adequate analgesia while avoiding the unwanted effects of large doses of any analgesic, in particular opioids. There are two reasons why we can hypothesize that multimodal analgesia might have a significant impact on cancer-related outcomes in the context of oncological orthopedic surgery. First, because multimodal analgesia is a key component of enhanced-recovery pathways and can accelerate return to intended oncological therapy. And second, because some of the analgesic used in multimodal analgesia (i.e., COX inhibitors, local analgesics and dexamethasone) can induce apoptosis in cancer cells and/or diminish the inflammatory response during surgery which itself can facilitate tumor growth.",
keywords = "cancer, enhanced recovery, multimodal analgesia, surgery, survival",
author = "Cata, {Juan P.} and Javier Lasala and Dario Bugada",
year = "2015",
doi = "10.2217/pmt.15.21",
language = "English",
volume = "5",
pages = "273--284",
journal = "Pain Management",
issn = "1758-1869",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Best practice in the administration of analgesia in postoncological surgery

AU - Cata, Juan P.

AU - Lasala, Javier

AU - Bugada, Dario

PY - 2015

Y1 - 2015

N2 - The rationale for using multimodal analgesia after any major surgery is achievement of adequate analgesia while avoiding the unwanted effects of large doses of any analgesic, in particular opioids. There are two reasons why we can hypothesize that multimodal analgesia might have a significant impact on cancer-related outcomes in the context of oncological orthopedic surgery. First, because multimodal analgesia is a key component of enhanced-recovery pathways and can accelerate return to intended oncological therapy. And second, because some of the analgesic used in multimodal analgesia (i.e., COX inhibitors, local analgesics and dexamethasone) can induce apoptosis in cancer cells and/or diminish the inflammatory response during surgery which itself can facilitate tumor growth.

AB - The rationale for using multimodal analgesia after any major surgery is achievement of adequate analgesia while avoiding the unwanted effects of large doses of any analgesic, in particular opioids. There are two reasons why we can hypothesize that multimodal analgesia might have a significant impact on cancer-related outcomes in the context of oncological orthopedic surgery. First, because multimodal analgesia is a key component of enhanced-recovery pathways and can accelerate return to intended oncological therapy. And second, because some of the analgesic used in multimodal analgesia (i.e., COX inhibitors, local analgesics and dexamethasone) can induce apoptosis in cancer cells and/or diminish the inflammatory response during surgery which itself can facilitate tumor growth.

KW - cancer

KW - enhanced recovery

KW - multimodal analgesia

KW - surgery

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84964695854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964695854&partnerID=8YFLogxK

U2 - 10.2217/pmt.15.21

DO - 10.2217/pmt.15.21

M3 - Article

VL - 5

SP - 273

EP - 284

JO - Pain Management

JF - Pain Management

SN - 1758-1869

IS - 4

ER -